Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 6,910,250 shares, an increase of 213.4% from the June 15th total of 2,204,864 shares. Approximately 9.8% of the company’s stock are sold short. Based on an average trading volume of 1,801,699 shares, the days-to-cover ratio is currently 3.8 days.
Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at 2.67 on Wednesday. The company’s 50-day moving average price is $2.59 and its 200-day moving average price is $1.78. The company’s market cap is $223.71 million. Catalyst Pharmaceuticals has a 12-month low of $0.68 and a 12-month high of $3.16.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Equities analysts anticipate that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current year.
A number of large investors have recently bought and sold shares of CPRX. Oxford Asset Management raised its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the period. Bank of New York Mellon Corp raised its stake in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the period. JPMorgan Chase & Co. purchased a new stake in Catalyst Pharmaceuticals during the first quarter valued at approximately $155,000. Berson & Corrado Investment Advisors LLC raised its stake in Catalyst Pharmaceuticals by 31.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 251,025 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 60,425 shares during the period. Finally, Knott David M purchased a new stake in Catalyst Pharmaceuticals during the first quarter valued at approximately $554,000. Hedge funds and other institutional investors own 30.09% of the company’s stock.
Separately, Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Monday, May 22nd.
WARNING: This report was posted by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-inc-nasdaqcprx-short-interest-update/1227100.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.